BRIDGEWATER, N.J. and BENGALURU, Karnataka, India, April 15, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon ...

AstraZenca is testing a once-daily PCSK9 inhibitor, currently known as AZD0780. After 12 weeks of use alongside standard ...

Regeneron’s (REGN) odronextamab was granted FDA orphan designation as a treatment of splenic marginal zone lymphoma, according to a post to the ...

The stock's fall snapped a two-day winning streak.

Shares of Regeneron Pharmaceuticals Inc. REGN rose 1.43% to $554.18 Friday, on what proved to be an all-around great trading ...

Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

Regeneron Pharmaceuticals saw its share price decline by 10% over the past week. The recent approval of Dupixent for COPD in Japan was expected to bolster investor confidence, yet the broader ...

Even as President Donald Trump paused the reciprocal tariffs for 90 days on Wednesday, he later confirmed in a conversation with reporters at his Oval Office that pharmaceutical companies would ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Phathom Pharmaceuticals (PHAT – Research ...

Regeneron Pharmaceuticals saw its share price decline by 10% over the past week. The recent approval of Dupixent for COPD in Japan was expected to bolster investor confidence, yet the broader market's ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other best extremely profitable stocks to buy according to analysts. We recently ...

Investors in Regeneron Pharmaceuticals, Inc. (Symbol: REGN) saw new options become available today, for the May 30th expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...